Abstract
The current standard to assess pentavalent antimonial (SSG) susceptibility of Leishmania is a laborious in vitro assay of which the result has little clinical value because SSG-resistant parasites are also found in SSG-cured patients. Candidate genetic markers for clinically relevant SSG-resistant parasites identified by full genome sequencing were here validated on a larger set of clinical strains. We show that 3 genomic locations suffice to specifically detect the SSG-resistant parasites found only in patients experiencing SSG treatment failure. This finding allows the development of rapid assays to monitor the emergence and spread of clinically relevant SSG-resistant Leishmania parasites.
| Original language | English |
|---|---|
| Journal | Journal of Infectious Diseases |
| Volume | 206 |
| Issue number | 5 |
| Pages (from-to) | 752-755 |
| Number of pages | 4 |
| ISSN | 0022-1899 |
| DOIs | |
| Publication status | Published - 2012 |
Keywords
- Protozoal diseases
- Visceral
- Leishmaniasis
- Kala azar
- Leishmania donovani
- Vectors
- Sandflies
- Phlebotomus argentipes
- Drug resistance
- SSG
- Antimonials
- Treatment failure
- Genetic markers
- Genome sequencing
- Strains
- Haplotypes
- Identification
- Assays
- India
- Asia-South
Fingerprint
Dive into the research topics of 'Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver